Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Investing.com -- AI-related stocks topped trading activity on Robinhood U.K. in June, led by Nvidia (NASDAQ: NVDA ), ...

Ozempic could help with his as a study by Goldman Sachs found that the mass-adoption of GLP-1 series drugs could allow for ...